Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 in previously treated hepatocellular carcinoma
CTR20131840Phase 3Completed
- Sponsor
- Polaris Group
- Start
- Mar 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Pegargiminase in hepatocellular carcinoma (HCC), sponsored by Polaris Group. Started Mar 2014; status: completed.
02
Drugs
Pegargiminase
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20131840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131840.